Grants per year
Personal profile
Training Experience
| 2003 | Residency, Royal College of Physicians, Ireland |
| 2009 | Fellowship, University of Texas Health Science Center, San Antonio |
| 2009 | Fellowship, Royal College of Physicians, Ireland |
Education/Academic qualification
PhD, Cancer Research, National University of Ireland
… → 2009
MBBChBAO, Medicine, National University of Ireland
… → 2000
Fingerprint
Dive into the research topics where Devalingam Mahalingam is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #CF33-CD19-101: A Phase I, Dose Escalation and Dose Expansion, Safety and Tolerability Study of onCARlytics (CF33-CD19), Administered Intravenously or Intratumorally in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumor
Mahalingam, D. (PD/PI)
Medpace Clinical Research LLC, Imugene Limited
8/9/24 → 8/9/27
Project: Research project
-
Prot #CP-MVC-101-01: A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic
Mahalingam, D. (PD/PI)
PPD Investigator Services, LLC, Takeda Development Center Americas, Inc.
4/22/24 → 4/22/27
Project: Research project
-
Prot #2138-CL-0101: A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Exp
Mahalingam, D. (PD/PI)
ICON Clinical Research, LLC, Astellas Pharma Global Development, Inc.
4/15/24 → 4/15/27
Project: Research project
-
Prot #M24-427: A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications
Mahalingam, D. (PD/PI)
3/13/24 → 3/13/27
Project: Research project
-
Prot #IMSA101-103: Phase 2 Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered with or without STING-Agonist IMSA101 in Patients with Oligoprogressive Solid Tumor Malignan
Mahalingam, D. (PD/PI)
Clinipace, Inc., ImmuneSensor Therapeutics, Inc.
12/15/23 → 12/15/26
Project: Research project
-
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)
Maldonado, E., Rathmell, W. K., Shapiro, G. I., Takebe, N., Rodon, J., Mahalingam, D., Trikalinos, N. A., Kalebasty, A. R., Parikh, M., Boerner, S. A., Balido, C., Krings, G., Burns, T. F., Bergsland, E. K., Munster, P. N., Ashworth, A., LoRusso, P. & Aggarwal, R. R., Jul 2024, In: Cancer research communications. 4, 7, p. 1793-1801 9 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers
Demir, T., Moloney, C. & Mahalingam, D., Jul 2024, In: Critical Reviews in Oncology/Hematology. 199, 104388.Research output: Contribution to journal › Review article › peer-review
-
Phase 1 clinical trials in refractory colorectal cancer: Do older patients benefit?
Vallejo, S., Mahalingam, D., Court, C., Ketchum, N., Gelfond, J., Michalek, J. & Arora, S. P., 2024, (Accepted/In press) In: Journal of Geriatric Oncology. 101816.Research output: Contribution to journal › Article › peer-review
-
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3b Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies
Carneiro, B. A., Cavalcante, L., Mahalingam, D., Saeed, A., Safran, H., Ma, W. W., Coveler, A. L., Powell, S., Bastos, B., Davis, E., Sahai, V., Mikrut, W., Longstreth, J., Smith, S., Weisskittel, T., Li, H., Borden, B. A., Harvey, R. D., Sahebjam, S. & Cervantes, A. & 6 others, , Feb 1 2024, In: Clinical Cancer Research. 30, 3, p. 522-531 10 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Safety and feasibility of establishing an adjuvant hepatic artery infusion program
Janczewski, L. M., Joung, R. H., Borhani, A. A., Lewandowski, R. J., Velichko, Y. S., Mulcahy, M. F., Mahalingam, D., Law, J., Bowman, C., Keswani, R. N., Poylin, V. Y., Bentrem, D. J. & Merkow, R. P., May 2024, In: HPB. 26, 5, p. 656-663 8 p.Research output: Contribution to journal › Article › peer-review
Datasets
-
Data for: Case Report of Prostate Ductal Adenocarcinoma Presenting with Hematuria
Pawlowski, J. (Contributor), Mahalingam, D. (Contributor) & Ha, C. S. (Contributor), Mendeley Data, May 18 2018
DOI: 10.17632/3kkg7vntxc.1, https://data.mendeley.com/datasets/3kkg7vntxc
Dataset